Neurocrine Biosciences Inc (NBIX): Total Assets
$4.63B
As of 2025-12-31
$5.36B
As of 2026-06-30
+25.0%
3-year compound annual growth
+21.7%
5-year compound annual growth
+25.6%
10-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $4.63B | +24.5% | 2026-02-11, Balance as of period end |
| 2024-12-31 | $3.72B | +14.4% | 2026-02-11, Balance as of period end |
| 2023-12-31 | $3.25B | +37.3% | 2025-02-10, Balance as of period end |
| 2022-12-31 | $2.37B | +14.3% | 2024-02-09, Balance as of period end |
| 2021-12-31 | $2.07B | +19.5% | 2023-02-09, Balance as of period end |
| 2020-12-31 | $1.73B | +32.8% | 2022-02-11, Balance as of period end |
| 2019-12-31 | $1.31B | +31.5% | 2021-02-05, Balance as of period end |
| 2018-12-31 | $993.15M | +21.5% | 2020-02-07, Balance as of period end |
| 2017-12-31 | $817.59M | +123.9% | 2019-02-08, Balance as of period end |
| 2016-12-31 | $365.09M | -23.1% | 2018-02-13, Balance as of period end |
| 2015-12-31 | $474.79M | +95.4% | 2017-02-14, Balance as of period end |
| 2014-12-31 | $243.03M | +57.1% | 2016-02-11, Balance as of period end |
| 2013-12-31 | $154.68M | -21.1% | 2015-02-09, Balance as of period end |
| 2012-12-31 | $195.98M | +41.6% | 2014-02-11, Balance as of period end |
| 2011-12-31 | $138.37M | -4.2% | 2013-02-08, Balance as of period end |
| 2010-12-31 | $144.42M | n/a | 2012-02-09, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Neurocrine Biosciences Inc (NBIX) | 2025-12-31 | $4.63B | +24.5% |
| Exelixis, Inc. (EXEL) | 2026-01-02 | $2.84B | -3.5% |
| Qiagen N.V. (QGEN) | 2025-12-31 | $6.28B | +10.4% |
| Moderna, Inc. (MRNA) | 2025-12-31 | $12.34B | -12.8% |
| Halozyme Therapeutics, Inc. (HALO) | 2025-12-31 | $2.53B | +22.4% |
| Bio-Techne Corp (TECH) | 2026-06-30 | $2.59B | +1.1% |
| Novavax Inc (NVAX) | 2025-12-31 | $1.18B | -24.6% |
| BioCryst Pharmaceuticals Inc (BCRX) | 2025-12-31 | $514.16M | +4.8% |
| Biogen Inc. (BIIB) | 2025-12-31 | $29.44B | +5.0% |
Compare NBIX, EXEL, QGEN, MRNA side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗